Cargando…

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production

BACKGROUND: While vaccination programs against the severe acute respiratory syndrome virus 2 (SARS-CoV-2) are globally ongoing, disparate strategies for the deployment of spike antigen show varying effectiveness. METHODS: In order to explore this phenomenon, we sought to compare the early immune res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Michael, Volzke, Johann, Subin, Behnam, Müller, Silke, Sombetzki, Martina, Reisinger, Emil C., Müller-Hilke, Brigitte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766223/ https://www.ncbi.nlm.nih.gov/pubmed/35042529 http://dx.doi.org/10.1186/s12916-022-02240-4

Ejemplares similares

Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2
por: Müller-Hilke, Brigitte, et al.
Publicado: (2022)

Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19
por: Müller, Michael, et al.
Publicado: (2022)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

AZD-1222: IgA-nephropathy: case report
Publicado: (2022)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition
por: Mai, Franz, et al.
Publicado: (2022)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022)

First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence
por: Murillo-Zamora, E., et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center
por: Costantino, Maria, et al.
Publicado: (2022)

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
por: Dag Berild, Jacob, et al.
Publicado: (2022)

AZD-1222: Severe bullous pemphigoid and IgA vasculitis: case report
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population
por: Tabatabaeifar, Sorosh, et al.
Publicado: (2023)

Degenerative Joint Damage Is Not a Risk Factor for Streptococcal Sepsis and Septic Arthritis in Mice
por: Volzke, Johann, et al.
Publicado: (2021)

AZD-1222: Leukocytoclastic vasculitis: 2 case reports
Publicado: (2022)

AZD-1222: Collapsing glomerulopathy: 2 case reports
Publicado: (2022)

AZD-1222: Various toxicities: 2 case reports
Publicado: (2022)

AZD 1222/tozinameran: Diabetes: 2 case reports
Publicado: (2022)

AZD-1222: Guillain-Barre syndrome
Publicado: (2021)

AZD-1222: Rhabdomyolysis: case report
Publicado: (2022)

AZD-1222: Polyarthralgia: case report
Publicado: (2021)

Azd-1222: Myelitis: case report
Publicado: (2022)

Azd-1222: Thrombocytopenia: case report
Publicado: (2022)

Azd-1222: Guillain-Barre-syndrome: 2 case reports
Publicado: (2021)

AZD-1222/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

AZD-1222: Herpes Zoster Ophthalmicus: 2 case reports
Publicado: (2022)

Azd-1222: Type 2 lepra reaction: case report
Publicado: (2022)

AZD-1222/tozinameran: Haemophagocytic-lymphohistiocytosis: 2 case reports
Publicado: (2022)

AZD-1222: Erythema nodosum leprosum: 2 case reports
Publicado: (2022)

Azd-1222: Acute Hemichorea-Hemiballismus: 2 case reports
Publicado: (2022)

Azd-1222: Superficial vein thrombosis: 2 case reports
Publicado: (2022)

Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2
por: Szabó, Enikő, et al.
Publicado: (2023)

AZD-1222: Nephrotic syndrome: case report
Publicado: (2021)

AZD-1222: Lack of efficacy: case report
Publicado: (2022)

AZD-1222: Immune thrombocytopenia: case report
Publicado: (2022)

AZD-1222: Leukocytoclastic vasculitis: case report
Publicado: (2022)

AZD-1222: Neck lymphadenitis: case report
Publicado: (2022)

AZD-1222: Immune thrombocytopenia: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2f3h9rphlq4k102nkv2ge8s1bm